DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA

NH MULDER; WTA VANDERGRAAF; PHB WILLEMSE; HS KOOPS; EGE DEVRIES; DT SLEIJFER

DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA

NH MULDER^*, WTA VANDERGRAAF, PHB WILLEMSE, HS KOOPS, EGE DEVRIES, DT SLEIJFER

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.

Original language	English
Pages (from-to)	681-683
Number of pages	3
Journal	British Jounal of Cancer
Volume	70
Issue number	4
Publication status	Published - Oct-1994

Keywords

INTERFERON ALPHA-2A ROFERON
METASTATIC MELANOMA
PHASE-II
BLEOMYCIN
VINDESINE

Handle.net

Persistent link

Cite this

@article{b49a6db4029b4852892860835d04b544,

title = "DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA",

abstract = "Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.",

keywords = "INTERFERON ALPHA-2A ROFERON, METASTATIC MELANOMA, PHASE-II, BLEOMYCIN, VINDESINE",

author = "NH MULDER and WTA VANDERGRAAF and PHB WILLEMSE and HS KOOPS and EGE DEVRIES and DT SLEIJFER",

year = "1994",

month = oct,

language = "English",

volume = "70",

pages = "681--683",

journal = "British Jounal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA

AU - MULDER, NH

AU - VANDERGRAAF, WTA

AU - WILLEMSE, PHB

AU - KOOPS, HS

AU - DEVRIES, EGE

AU - SLEIJFER, DT

PY - 1994/10

Y1 - 1994/10

N2 - Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.

AB - Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.

KW - INTERFERON ALPHA-2A ROFERON

KW - METASTATIC MELANOMA

KW - PHASE-II

KW - BLEOMYCIN

KW - VINDESINE

M3 - Article

SN - 0007-0920

VL - 70

SP - 681

EP - 683

JO - British Jounal of Cancer

JF - British Jounal of Cancer

IS - 4

ER -

DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA

Abstract

Keywords

Handle.net

Fingerprint

Cite this